Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Five Antipsychotics in Psychiatric Patients
NCT02087579Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of aripiprazole, olanzapine, paliperidone, quetiapine (extended-release tablet, brand name: Bipresso) and risperidone in psychotic disorders, schizophrenia, bipolar disorder (BD) and 1 more (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Aripiprazole concentration in venous and capillary plasma, Paliperidone concentration in venous and capillary plasma and 3 more. Started Feb 2014; status: completed.
02
Drugs
aripiprazoleolanzapinepaliperidonequetiapine (extended-release tablet, brand name: Bipresso)risperidone
03
Conditions
psychotic disordersschizophreniabipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02087579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02087579.